Literature DB >> 30478767

Long-Term Efficacy of Peroral Endoscopic Myotomy for Patients with Achalasia: Outcomes with a Median Follow-Up of 36 Months.

Chenghai He1, Meng Li1, Bin Lu2, Xiao Ying1, Chen Gao1, Shuangshuang Wang1, Chengao Ma1, Chaoqiong Jin1.   

Abstract

OBJECTIVE: This study aimed to evaluate the long-term efficacy of peroral endoscopic myotomy (POEM) for patients with achalasia.
METHODS: Prospective data collected from 115 patients (median age 45 years; interquartile range 34-57) with achalasia who underwent POEM at the First Affiliated Hospital of ZheJiang Chinese Medical University with a median follow-up of 36 months were retrospectively analyzed. The Eckardt score and lower esophageal sphincter pressure changes were analyzed, and the gastroesophageal reflux was observed.
RESULTS: During the final follow-up, the mean Eckardt score reduced from 7.5 ± 1.9 preoperatively to 2.3 ± 1.4 after 1 month of surgery (P < 0.001). Treatment success was observed in 91.3% [confidence interval (CI) 86.2-96.4], 90.3% (CI 84.8-95.8), 89.0% (CI 83.1-94.9), 83.7% (CI 75.7-91.7), and 80.1% (CI 69.7-90.5) of patients after 12, 24, 36, 48, and 60 months, respectively. A total of 16 (13.9%) failures occurred. Four patients were nonresponders (failure within 3 months), eight had an early recurrence (between 3 months and 3 years), and four had a late recurrence (after 3 years). Further, 21 (20.6%) patients had symptoms of reflux during the two-year follow-up. Only one patient with symptomatic reflux was newly added during the subsequent three-year follow-up. Moreover, 71 (61.7%) patients underwent gastroscopy after POEM, and 13 (18.3%) patients were diagnosed with reflux esophagitis.
CONCLUSION: POEM is safe and effective in treating achalasia and has a favorable long-term efficacy.

Entities:  

Keywords:  Achalasia; Gastroesophageal reflux; Long-term effects; Peroral endoscopic myotomy

Mesh:

Year:  2018        PMID: 30478767     DOI: 10.1007/s10620-018-5373-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  Clinical response to peroral endoscopic myotomy in patients with idiopathic achalasia at a minimum follow-up of 2 years.

Authors:  Yuki B Werner; Guido Costamagna; Lee L Swanström; Daniel von Renteln; Pietro Familiari; Ahmed M Sharata; Tania Noder; Guido Schachschal; Jan F Kersten; Thomas Rösch
Journal:  Gut       Date:  2015-04-30       Impact factor: 23.059

2.  Outcomes of per-oral endoscopic myotomy for treatment of esophageal achalasia with a median follow-up of 49 months.

Authors:  Quan-Lin Li; Qiu-Ning Wu; Xiao-Cen Zhang; Mei-Dong Xu; Wei Zhang; Shi-Yao Chen; Yun-Shi Zhong; Yi-Qun Zhang; Wei-Feng Chen; Wen-Zheng Qin; Jian-Wei Hu; Ming-Yan Cai; Li-Qing Yao; Ping-Hong Zhou
Journal:  Gastrointest Endosc       Date:  2017-11-03       Impact factor: 9.427

3.  Multimedia manuscript. Heller myotomy and intraluminal fundoplication: a NOTES technique.

Authors:  Silvana Perretta; Bernard Dallemagne; Pierre Allemann; Pierre Alleman; Jacques Marescaux
Journal:  Surg Endosc       Date:  2010-04-29       Impact factor: 4.584

4.  Submucosal fibrosis in achalasia patients is a rare cause of aborted peroral endoscopic myotomy procedures.

Authors:  Qiu-Ning Wu; Xiao-Yue Xu; Xiao-Cen Zhang; Mei-Dong Xu; Yi-Qun Zhang; Wei-Feng Chen; Ming-Yan Cai; Wen-Zheng Qin; Jian-Wei Hu; Li-Qing Yao; Quan-Lin Li; Ping-Hong Zhou
Journal:  Endoscopy       Date:  2017-06-28       Impact factor: 10.093

5.  Effect of peroral esophageal myotomy for achalasia treatment: A Chinese study.

Authors:  Bin Lu; Meng Li; Yue Hu; Yi Xu; Shuo Zhang; Li-Jun Cai
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

6.  Peroral endoscopic myotomy for achalasia cardia: Treatment analysis and follow up of over 200 consecutive patients at a single center.

Authors:  Mohan Ramchandani; D Nageshwar Reddy; Santosh Darisetty; Rama Kotla; Radhika Chavan; Rakesh Kalpala; Domenico Galasso; Sundeep Lakhtakia; G V Rao
Journal:  Dig Endosc       Date:  2015-07-30       Impact factor: 7.559

7.  Refractory GERD: increased body mass index is associated with persisting acid exposure but not hypersensitive esophagus or functional heartburn.

Authors:  Nikos Viazis; George P Karamanolis; Jiannis Anastasiou; Anastasia Keyoglou; Jiannis Vlachogiannakos; Spiros D Ladas; Dimitrios G Karamanolis
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-12       Impact factor: 2.566

8.  Long-term results of the European achalasia trial: a multicentre randomised controlled trial comparing pneumatic dilation versus laparoscopic Heller myotomy.

Authors:  An Moonen; Vito Annese; Ann Belmans; Albert J Bredenoord; Stanislas Bruley des Varannes; Mario Costantini; Bertrand Dousset; J I Elizalde; Uberto Fumagalli; Marianne Gaudric; Antonio Merla; Andre J Smout; Jan Tack; Giovanni Zaninotto; Olivier R Busch; Guy E Boeckxstaens
Journal:  Gut       Date:  2015-11-27       Impact factor: 23.059

9.  Long-term quality of life after peroral endoscopic myotomy remains compromised in patients with achalasia type III.

Authors:  Oscar V Hernández Mondragón; Marina A González Martinez; Juan M Blancas Valencia; Maria L Hernandez Reyes; Omar M Solórzano Pineda; Gerardo Blanco Velasco
Journal:  Endoscopy       Date:  2017-09-12       Impact factor: 10.093

Review 10.  GERD after per-oral endoscopic myotomy as compared with Heller's myotomy with fundoplication: a systematic review with meta-analysis.

Authors:  Alessandro Repici; Lorenzo Fuccio; Roberta Maselli; Fabrizio Mazza; Loredana Correale; Daniele Mandolesi; Cristina Bellisario; Amrita Sethi; Mouen A Khashab; Thomas Rösch; Cesare Hassan
Journal:  Gastrointest Endosc       Date:  2017-11-02       Impact factor: 9.427

View more
  7 in total

1.  Clinical Success and Correlation of Eckardt Scores with Barium Esophagram After Peroral Endoscopic Myotomy in Achalasia.

Authors:  Madhusudan R Sanaka; Pravallika Chadalavada; Fahrettin Covut; George Khoudari; Scott Gabbard; Prashanthi N Thota; Siva Raja
Journal:  J Gastrointest Surg       Date:  2020-09-03       Impact factor: 3.452

2.  Mid-Term and Long-Term Outcomes of Peroral Endoscopic Myotomy for the Treatment of Achalasia: A Systematic Review and Meta-Analysis.

Authors:  Han Zhang; Xinyi Zeng; Shu Huang; Lei Shi; Huifang Xia; Jiao Jiang; Wensen Ren; Yan Peng; Muhan Lü; Xiaowei Tang
Journal:  Dig Dis Sci       Date:  2022-10-19       Impact factor: 3.487

3.  Outcomes of 100 Patients More Than 4 Years After POEM for Achalasia.

Authors:  Ryan A J Campagna; Arturo Cirera; Amy L Holmstrom; Joseph R Triggs; Ezra N Teitelbaum; Dustin A Carlson; John E Pandolfino; Eric S Hungness
Journal:  Ann Surg       Date:  2021-06-01       Impact factor: 13.787

4.  Peroral endoscopic longer vs shorter esophageal myotomy for achalasia treatment: A systematic review and meta-analysis.

Authors:  Chun-Yan Weng; Cheng-Hai He; Ming-Yang Zhuang; Jing-Li Xu; Bin Lyu
Journal:  World J Gastrointest Surg       Date:  2022-03-27

5.  Endoscopic ultrasound-measured muscular thickness of the lower esophageal sphincter and long-term prognosis after peroral endoscopic myotomy for achalasia.

Authors:  Ye Liao; Ting-Yue Xiao; Yu-Fan Wu; Jing-Jing Zhang; Bao-Zhen Zhang; Yi-Dan Wang; Sheng Wang; Xiang Liu; Si-Yu Sun; Jin-Tao Guo
Journal:  World J Gastroenterol       Date:  2020-10-14       Impact factor: 5.742

6.  Modified Peroral Endoscopic Myotomy Technique for Type II Achalasia: A Multicenter Retrospective Study.

Authors:  Huahui Zhang; Kuangjing Wang; Ying Fang; Zhe Xiong; Min Lin; Lifeng Jiang; Qiuya Niu; Jin Huang
Journal:  Gastroenterol Res Pract       Date:  2022-03-25       Impact factor: 2.260

7.  Efficacy and Safety of Peroral Endoscopic Myotomy for Esophageal Achalasia and Achalasia-Related Diseases in Patients Aged 75 Years and Over.

Authors:  Jun Nakamura; Takuto Hikichi; Minami Hashimoto; Mika Takasumi; Tsunetaka Kato; Ryoichiro Kobashi; Takumi Yanagita; Rei Suzuki; Mitsuru Sugimoto; Yuki Sato; Hiroki Irie; Tadayuki Takagi; Masao Kobayakawa; Hiromasa Ohira
Journal:  Healthcare (Basel)       Date:  2021-12-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.